Effect of hematuria on the outcome of immunoglobulin A nephropathy with proteinuria

Chihiro Iwasaki ¹, Takahito Moriyama ¹ * , Kayu Tanaka ¹, Takashi Takei ¹, Kosaku Nitta ¹

Cited by CrossRef: 18

1- Matsuzaki K, Suzuki H, Kawamura T, Tomino Y, Suzuki Y. Utility of remission criteria for the renal prognosis of IgA nephropathy. Clin Exp Nephrol. 2021;25(9):988 [Crossref]

2- Glassock R. Moderator's view: Treatment of IgA nephropathy—getting comfortable with uncertainty. Nephrol Dial Transplant. 2016;31(11):1776 [Crossref]

3- Coppo R. Clinical and histological risk factors for progression of IgA nephropathy: an update in children, young and adult patients. J Nephrol. 2017;30(3):339 [Crossref]

4- Yu G, Guo L, Dong J, Shi S, Liu L, Wang J, Sui G, Zhou X, Xing Y, Li H, Lv J, Zhang H. Persistent Hematuria and Kidney Disease Progression in IgA Nephropathy: A Cohort Study. American Journal of Kidney Diseases. 2020;76(1):90 [Crossref]

5- Kawamura T, Hirano K, Koike K, Nishikawa M, Shimizu A, Joh K, Katafuchi R, Hashiguchi A, Matsuzaki K, Maruyama S, Tsuboi N, Narita I, Yano Y, Yokoo T, Suzuki Y. Associations of corticosteroid therapy and tonsillectomy with kidney survival in a multicenter prospective study for IgA nephropathy. Sci Rep. 2023;13(1) [Crossref]

6- Filippone E, Gulati R, Farber J. Contemporary review of IgA nephropathy. Front Immunol. 2024;15 [Crossref]

7- Bobart S, Alexander M, Shawwa K, Vaughan L, Ghamrawi R, Sethi S, Cornell L, Glassock R, Fervenza F, Zand L. The association of microhematuria with mesangial hypercellularity, endocapillary hypercellularity, crescent score and renal outcomes in immunoglobulin A nephropathy. 2021;36(5):840 [Crossref]

8- Coppo R, Fervenza F. Persistent Microscopic Hematuria as a Risk Factor for Progression of IgA Nephropathy: New Floodlight on a Nearly Forgotten Biomarker. JASN. 2017;28(10):2831 [Crossref]

9- He P, Wang H, Huang C, He L. Hematuria was a high risk for renal progression and ESRD in immunoglobulin a nephropathy: a systematic review and meta-analysis. Renal Failure. 2021;43(1):488 [Crossref]

10- Ebbestad R, Sanaei Nurmi M, Lundberg S. Long-Term Outcomes of Patients with IgA Nephropathy Categorized by the International IgAN Risk Prediction Tool and by the Degree of Hematuria at Diagnosis. Nephron. 2022;146(6):573 [Crossref]

11- Sevillano A, Gutiérrez E, Yuste C, Cavero T, Mérida E, Rodríguez P, García A, Morales E, Fernández C, Martínez M, Moreno J, Praga M. Remission of Hematuria Improves Renal Survival in IgA Nephropathy. JASN. 2017;28(10):3089 [Crossref]

12- Moriyama T. Clinical and histological features and therapeutic strategies for IgA nephropathy. Clin Exp Nephrol. 2019;23(9):1089 [Crossref]

13- Tan J, Luo X, Yang J, Liu N, Jiang Z, Tang Y, Qin W. Clinicopathological characteristics and risk factors in elderly patients with biopsy-proven IgA nephropathy. Renal Failure. 2022;44(1):1027 [Crossref]

14- Yano Y, Nagasu H, Kanegae H, Nangaku M, Hirakawa Y, Sugawara Y, Nakagawa N, Wada J, Sugiyama H, Nakano T, Wada T, Shimizu M, Suzuki H, Komatsu H, Nakashima N, Kitaoka K, Narita I, Okada H, Suzuki Y, Kashihara N. Kidney outcomes associated with haematuria and proteinuria trajectories among patients with IgA nephropathy in real‐world clinical practice: The Japan Chronic Kidney Disease Database. Nephrology. 2024;29(2):65 [Crossref]

15- Toda M, Kume A, Hara M, Kimura H, Nakamura Y, Okumura K, Beppu H, Nakamura Y, Ogawa H, Kamei Y, Ishiwatari A, Kawanishi T, Ogawa T, Abe Y, Endo M, Wakai S. Efficacy and limitations of additional steroid pulse therapy in IgA nephropathy patients whose hematuria did not remit on tonsillectomy and protocol steroid pulse therapy. Clin Exp Nephrol. 2022;26(9):859 [Crossref]

16- Peruzzi L, Cocchi E, Tarizzo F. Old and New Treatment Options in IgA Nephropathy and Henoch Schönlein Purpura Nephritis/IgA Vasculitis in Children. Curr Treat Options Peds. 2019;5(3):236 [Crossref]

17- Mastrangelo A, Serafinelli J, Giani M, Montini G. Clinical and Pathophysiological Insights Into Immunological Mediated Glomerular Diseases in Childhood. Front Pediatr. 2020;8 [Crossref]

18- Zand L, Fervenza F, Coppo R. Microscopic hematuria as a risk factor for IgAN progression: considering this biomarker in selecting and monitoring patients. 2023;16(Supplement_2):ii19 [Crossref]